SCHEMBL10312234

SCHEMBL10312234

C/C=C/c1cc(Nc2nc(/C=C/c3cccc(C(F)(F)F)c3)nc(N3CCN(C)CC3)n2)n[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 10/20 0.61
USP2 O75604 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
AURKA O14965 3/20 0.43
AURKB Q96GD4 3/20 0.43
PLK4 O00444 2/20 0.43
ABL1 P00519 2/20 0.43
NTRK1 P04629 2/20 0.43
LCK P06239 2/20 0.43
CSF1R P07333 2/20 0.43
RET P07949 2/20 0.43
KIT P10721 2/20 0.43
FGFR1 P11362 2/20 0.43
SRC P12931 2/20 0.43
PDGFRA P16234 2/20 0.43
TYK2 P29597 2/20 0.43
KDR P35968 2/20 0.43
FLT3 P36888 2/20 0.43
PTK2 Q05397 2/20 0.43
MAP4K5 Q9Y4K4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16556933 0.93 HRH4 (0.51) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312230 0.92 IDH2 (0.52) HRH4USP2SMN1; SMN2AURKAAURKB
SCHEMBL10312124 0.91 HRH4 (0.50) HRH4USP2SMN1; SMN2AURKAAURKB
SCHEMBL10312231 0.91 HRH4 (0.49) HRH4USP2SMN1; SMN2IDH2MAPT
SCHEMBL10312151 0.90 HRH4 (0.49) HRH4USP2SMN1; SMN2AURKAAURKB
SCHEMBL10312081 0.90 HRH4 (0.62) HRH4USP2SMN1; SMN2AURKAAURKB
SCHEMBL10312094 0.89 HRH4 (0.59) HRH4AURKAAURKBPLK4ABL1
SCHEMBL10312182 0.88 AURKA (0.55) HRH4AURKAAURKBPLK4ABL1
SCHEMBL10312156 0.87 HRH4 (0.59) HRH4AURKAAURKBPLK4ABL1
SCHEMBL16556877 0.87 HRH4 (0.59) HRH4USP2SMN1; SMN2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440055-B1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY LLC (US) 2015-03-11 EP disclosed
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178758-A1 STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS STK25, STK35, SGK2 HRH4 2393/4885USP2 1096/4885SMN1; SMN2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.